We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.27B
AUM Growth
+$432M
Cap. Flow
+$259M
Cap. Flow %
7.92%
Top 10 Hldgs %
37.03%
Holding
113
New
28
Increased
27
Reduced
21
Closed
27

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$111M
2
MYGN icon
Myriad Genetics
MYGN
+$77.2M
3
BAX icon
Baxter International
BAX
+$36.4M
4
BFLY icon
Butterfly Network
BFLY
+$36.2M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$35.7M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$52.7M
2
IRTC icon
iRhythm Holdings
IRTC
+$40.6M
3
PEN icon
Penumbra
PEN
+$32.4M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.98%
2 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLV icon
1
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.7B
$185M 5.65%
+1,585,000
New +$183M
OM icon
2
Outset Medical
OM
$78M
$164M 5%
200,847
+6,767
+3% +$5.22M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$162M 4.95%
1,059,631
+78,500
+8% +$12.1M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$146M 4.46%
1,587,348
+258,545
+19% +$21.8M
NBIX icon
5
Neurocrine Biosciences
NBIX
$17.5B
$103M 3.13%
+1,055,510
New +$111M
ABBV icon
6
AbbVie
ABBV
$453B
$100M 3.06%
926,823
– –
RCUS icon
7
Arcus Biosciences
RCUS
$3.73B
$98.2M 3%
3,498,260
+124,800
+4% +$4.34M
LLY icon
8
Eli Lilly
LLY
$1.05T
$98.2M 3%
525,455
+174,810
+50% +$34.2M
MYGN icon
9
Myriad Genetics
MYGN
$538M
$82.8M 2.53%
+2,718,623
New +$77.2M
HCA icon
10
HCA Healthcare
HCA
$83.5B
$73.5M 2.25%
390,507
+77,020
+25% +$13.6M
GILD icon
11
Gilead Sciences
GILD
$163B
$69.5M 2.12%
1,075,063
+133,389
+14% +$8.6M
MCK icon
12
McKesson
MCK
$96.4B
$69.5M 2.12%
356,231
+47,244
+15% +$8.62M
IQV icon
13
IQVIA
IQV
$34.5B
$69.1M 2.11%
357,916
-15,385
-4% -$2.89M
UHS icon
14
Universal Health Services
UHS
$9.13B
$65M 1.98%
487,000
+44,956
+10% +$5.96M
AVTR icon
15
Avantor
AVTR
$7.76B
$64.5M 1.97%
2,229,657
+155,398
+7% +$4.49M
NVRO
16
DELISTED
NEVRO CORP.
NVRO
$62.1M 1.9%
444,877
+132,937
+43% +$21.7M
IBB icon
17
PUT
iShares Biotechnology ETF
IBB
$9.35B
$61.5M 1.88%
+408,500
New +$64.9M
ICUI icon
18
ICU Medical
ICUI
$3.84B
$59.7M 1.82%
290,661
+22,844
+9% +$4.82M
HUM icon
19
Humana
HUM
$47.3B
$59.7M 1.82%
142,406
+64,666
+83% +$25.8M
UNH icon
20
UnitedHealth
UNH
$384B
$54.1M 1.65%
145,295
+43,196
+42% +$15M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$53.1M 1.62%
309,780
+100,774
+48% +$20M
XBI icon
22
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$47.5M 1.45%
+350,000
New +$52.4M
EW icon
23
Edwards Lifesciences
EW
$48.1B
$42.9M 1.31%
513,005
+25,163
+5% +$2.13M
MYOV
24
DELISTED
Myovant Sciences Ltd.
MYOV
$42.3M 1.29%
2,054,928
+1,008,716
+96% +$23M
PPD
25
DELISTED
PPD, Inc. Common Stock
PPD
$41.5M 1.27%
1,096,492
+353,629
+48% +$12.7M
1
2 3 4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q1 2021 Portfolio in Review

As of Q1 2021, PFM Health Sciences held 113 positions worth $3.27B, up 15% from $2.84B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

PFM Health Sciences deployed $259M of net new capital in Q1 2021, opening 28 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,055,510 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 79% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Penumbra, an estimated $32.4M trimmed.

  • PFM Health Sciences's largest Q1 2021 buy was Neurocrine Biosciences: 1,055,510 shares worth $103M.
  • PFM Health Sciences added most to Eli Lilly in Q1 2021, an estimated $34.2M increase.
  • PFM Health Sciences's biggest Q1 2021 reduction was Penumbra, cutting an estimated $32.4M.
  • PFM Health Sciences fully exited Elevance Health in Q1 2021, selling an estimated $52.7M.
  • PFM Health Sciences's ten largest holdings make up 37% of its $3.27B portfolio in Q1 2021.
  • PFM Health Sciences opened 28 new positions and closed 27 in Q1 2021.
  • PFM Health Sciences's portfolio value rose 15% quarter-over-quarter to $3.27B.

Based on PFM Health Sciences's 13F filing for Q1 2021, filed 17 May 2021.